Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lercanidipine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.60 |
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lercanidipine SCHEMBL29541187 | 1.00 | ADORA3 (1.00) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| Lercanidipine SCHEMBL31429659 | 1.00 | ADORA3 (1.00) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| Lercanidipine SCHEMBL30158506 | 1.00 | ADORA3 (1.00) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| Lercanidipine SCHEMBL9957683 | 1.00 | ADORA3 (1.00) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| Lercanidipine SCHEMBL1819021 | 1.00 | ADORA3 (1.00) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| Lercanidipine SCHEMBL25268 | 1.00 | ADORA3 (1.00) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| Lercanidipine SCHEMBL8415026 | 1.00 | ADORA3 (1.00) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| Lercanidipine SCHEMBL4730008 | 0.99 | ADORA3 (0.98) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| Lercanidipine SCHEMBL8630225 | 0.99 | ADORA3 (0.98) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| Lercanidipine SCHEMBL29349606 | 0.99 | ADORA3 (0.98) | ADORA3ADRA1AMTORRAB9ASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8428 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741492-A2 | NECROSIS INHIBITOR | Linkgevity Limited (GB) | 2026-05-13 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-20260069593-A1 | METHODS FOR TREATING CANCER | AMGEN INC (US) | 2026-03-12 | — | — | US | claimed |
| EP-4648769-A2 | NECROSIS INHIBITOR | Linkgevity Limited (GB) | 2025-11-19 | — | — | EP | claimed |
| US-20250345332-A1 | APROCITENTAN FOR THE TREATMENT OF HYPERTENSION | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-11-13 | — | — | US | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| US-20250281447-A1 | SIGMA-1 RECEPTOR AGONIST SYSTOLIC BLOOD PRESSURE THERAPY | ANAVEX LIFE SCIENCES CORP. | 2025-09-11 | — | — | US | claimed |
| US-20250248940-A1 | Biopolymer Formulations for Drug Delivery | 11584022 CANADA INC. (CA) | 2025-08-07 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| WO-2025101983-A1 | NON-STEROIDAL ISONITRILE BINDING COMPOUNDS OF CYTOCHROME P450 SUBTYPES | BRANDEIS UNIVERSITY (US) | 2025-05-15 | — | — | WO | claimed |
| WO-1999047172-A2 | ORAL PHARMACEUTICAL COMPOSITIONS TO BE TAKEN WITHOUT LIQUIDS, WHICH CONTAIN INCLUSION COMPLEXES | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1999-09-23 | — | — | WO | claimed |
| EP-0839036-B1 | USE OF 1,4-DIHYDROPYRIDINE DERIVATIVES IN THE PREVENTION AND THERAPY OF ATHEROSCLEROTIC DEGRADATION OF ARTERIAL WALLS | RECORDATI CHEM PHARM (IT) | 1999-08-25 | — | — | EP | claimed |
| WO-1998036733-A2 | TOPICAL PHARMACEUTICAL COMPOSITION COMPRISING A CHOLINERGIC AGENT OR A CALCIUM CHANNEL BLOCKER | KAMM MICHAEL ALBERT (GB) | 1998-08-27 | — | — | WO | claimed |
| CN-1190345-A | Use of 1,4-dihydropyridine derivative in prevention and therapy of atherosclerotic degradation of arterial walls | RECORDATI CHEM PHARM (CH) | 1998-08-12 | — | — | CN | claimed |
| US-5767136-A | ADMINISTERING TO REDUCE MIGRATION OF CELLS, REDUCE BUILD UP OF CONNECTIVE TISSUE, OR PREVENT LIPID ACCUMULATION IN THE BLOOD VESSELS | RECORDATI, S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1998-06-16 | — | — | US | claimed |
| CN-1184468-A | A process for the preparation of lercanidipine hydrochloride | RECORDATI CHEM PHARM (CH) | 1998-06-10 | — | — | CN | claimed |
| EP-0839036-A1 | USE OF 1,4-DIHYDROPYRIDINE DERIVATIVES IN THE PREVENTION AND THERAPY OF ATHEROSCLEROTIC DEGRADATION OF ARTERIAL WALLS | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 1998-05-06 | — | — | EP | claimed |
| EP-0824517-A1 | A PROCESS FOR THE PREPARATION OF LERCANIDIPINE HYDROCHLORIDE | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 1998-02-25 | — | — | EP | claimed |
| WO-1997003669-A1 | USE OF 1,4-DIHYDROPYRIDINE DERIVATIVES IN THE PREVENTION AND THERAPY OF ATHEROSCLEROTIC DEGRADATION OF ARTERIAL WALLS | RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1997-02-06 | — | — | WO | claimed |
| WO-1996035668-A1 | A PROCESS FOR THE PREPARATION OF LERCANIDIPINE HYDROCHLORIDE | RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1996-11-14 | — | — | WO | claimed |